Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)

被引：1

作者：

Franklin, Anna ^{[1
]}

Zecca, Marco ^{[2
]}

Fagioli, Franca ^{[3
]}

Luisi, Flavio Augusto ^{[4
]}

Song, Gregory ^{[5
]}

Suri, Ajit ^{[5
]}

Leonard, E. Jane ^{[5
]}

Locatelli, Franco ^{[6
]}

机构：

[1] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO USA

[2] Fdn IRCCS Policlin San Matteo, Pediat Hematol Oncol, Pavia, Italy

[3] Univ Turin, Childrens Hosp Regina Margherita, Turin, Italy

[4] Grp Apoio Ao Adolescente & Crianca Com Canc, Sao Paulo, Brazil

[5] Millennium Pharmaceut Inc, Cambridge, MA USA

[6] IRCCS Osped Pediat Bambino Gesu, Dept Pediat Hematol Oncol & Cell & Gene Therapy, Rome, Italy

来源：

关键词：

D O I：

10.1182/blood-2018-99-112488

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1644

引用

页数：2